
Sanofi takes over Bioverativ in US$11.8bn deal
The deal will boost Sanofi's pipeline in the growing hemophilia and orphan blood disorders market. Biogen hemophilia spin-out Bioverativ has two...

Inhaled IL-4 halts neuron destruction in MS models
The researchers headed by Frauke Zipp from University Hospital Mainz, Germany, say their findings could pave the way toward unconventional and...

EU General Court rejects industry’s confidentiality claims
In all three cases, the EMA granted access to documents under the EU’s transparency policy (Zitat), which were part of the companies submission for...

Bioeconomy: Bringing in the public
In three years of work, the BioSTEP experts from five European countries organised discussions, workshops, conferences or living lab...

Novartis in US$170m licence deal with Spark Therapeutics
The Swiss pharma major paid US$105m upfront for the commercialisation rights for the first-in-class gene therapy Luxturna outside the US market....

Convert Pharmaceuticals SA closes €13.6m Series A round
The proceeds will be used to prepare and conduct Phase I clinical studies with Convert's nitroaromatic lead anti-cancer drug CP-506, which may bring...

Sanofi’s alirocumab improves cardiovascular event rate over statins
The PCSK9 inhibitor, which lowered blood lipids by 40-60% in previous trails, reduced the risk of MACE by 15% and was associated with a...